Signature of a license agreement between 4P-Pharma, SATT-Aquitaine and University of Bordeaux for the development of an anti-cancer drug.
Talence, September 1st
4P-Pharma has signed an exclusive license agreement with Aquitaine Science Transfert, for the development of a drug targeting pancreatic cancer, triple negative breast cancer or colon cancer. The molecule was first developed and patented by researchers from the laboratory of Angiogenesis and Cancer Microenvironment (LAMC – University of Bordeaux / Inserm).This signature materializes the technology transfer process managed by Inserm Transfert and the SATT Aquitaine. The funding for the project maturation amounts to 375 k€ over a 3-year time frame.